Mereo BioPharma (MREO) : 5-year performance

• Mereo BioPharma (MREO) was founded in March 2015 to fund and develop high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies.
• It acquired a portfolio of three product candidates from Novartis in July 2015 and a fourth product from AstraZeneca in October 2017. In April 2019, Mereo merged with OncoMed, a Nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing novel oncology products.
• OncoMed Pharmaceuticals (OMED) had its IPO on Jul 17, 2013. The company sold 4.8 million shares at $17, above the $14 to $16 shares range laid out earlier. The offering raised $82 million.